Skip to main content

Articles

Page 5 of 64

  1. Previous research has extensively documented the impact of migraine episodes (‘ictal’) on patients’ health-related quality of life. Few studies have looked at the impact of migraine on migraine-free days (‘int...

    Authors: Lena T. Hubig, Timothy Smith, Emma Williams, Lauren Powell, Karissa Johnston, Linda Harris, Gilbert L’Italien, Vladimir Coric, Andrew J. Lloyd and Siu Hing Lo
    Citation: The Journal of Headache and Pain 2022 23:97
    Content type: Research Published on:

  2. The diagnosis of migraine is mainly clinical and self-reported, which makes additional examinations unnecessary in most cases. Migraine can be subtyped into chronic (CM) and episodic (EM). Despite the very hig...

    Authors: Javier Gomez-Pilar, Víctor Martínez-Cagigal, David García-Azorín, Carlos Gómez, Ángel Guerrero and Roberto Hornero
    Citation: The Journal of Headache and Pain 2022 23:95
    Content type: Review Published on:

  3. Authors: Saeid Safiri, Ali-Asghar Kolahi, Maryam Noori, Seyed Aria Nejadghaderi, Armin Aslani, Mark J. M. Sullman, Mehdi Farhoudi, Mostafa Araj-Khodaei, Gary S. Collins, Jay S. Kaufman and Kurosh Gharagozli
    Citation: The Journal of Headache and Pain 2022 23:94
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2022 23:77

  4. Headache is among the most frequent symptoms persisting or newly developing after coronavirus disease 2019 (COVID-19) as part of the so-called long COVID syndrome. The knowledge on long COVID headache is still...

    Authors: Claudio Tana, Enrico Bentivegna, Soo-Jin Cho, Andrea M. Harriott, David García-Azorín, Alejandro Labastida-Ramirez, Raffaele Ornello, Bianca Raffaelli, Eloísa Rubio Beltrán, Ruth Ruscheweyh and Paolo Martelletti
    Citation: The Journal of Headache and Pain 2022 23:93
    Content type: Review Published on:

  5. There have been a few studies regarding the pre-attack symptoms (PAS) and pre-episode symptoms (PES) of cluster headache (CH), but none have been conducted in the Chinese population. The purpose of this study ...

    Authors: Ke Li, Shuping Sun, Zhanyou Xue, Sufen Chen, Chunyang Ju, Dongmei Hu, Xiaoyu Gao, Yanhong Wang, Dan Wang, Jianjun Chen, Li Li, Jing Liu, Mingjie Zhang, Zhihua Jia, Xun Han, Huanxian Liu…
    Citation: The Journal of Headache and Pain 2022 23:92
    Content type: Consensus Article Published on:

  6. The benefits of preventive treatment on the effectiveness of migraine management have rarely been examined. This post hoc analysis investigated the impact of eptinezumab on the optimization of acute medication...

    Authors: Roger Cady, Richard B. Lipton, Dawn C. Buse, Mette Krog Josiassen, Annika Lindsten and Anders Ettrup
    Citation: The Journal of Headache and Pain 2022 23:91
    Content type: Research Published on:

  7. Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials. We repor...

    Authors: Bo Hu, Gang Li, Xiaohong Li, Shan Wu, Tingmin Yu, Xiang Li, Hongru Zhao, Zhihua Jia, Junpeng Zhuang and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2022 23:90
    Content type: Research Published on:

  8. The aim of the study was to investigate whether MwoA and MwA are different manifestations of a single disease, distinct clinical entities, or located at two poles of a spectrum.

    Authors: Ye Ran, Ziming Yin, Yajun Lian, Yanmei Xu, Yajie Li, Jiale Liu, Qun Gu, Fanhong Yan, Zhaoli Ge, Yu Lian, Dongmei Hu, Sufen Chen, Yangyang Wang, Xiaolin Wang, Rongfei Wang, Xiaoyan Chen…
    Citation: The Journal of Headache and Pain 2022 23:89
    Content type: Research Published on:

  9. Previous studies revealed inconsistent results regarding association between migraine and cognitive impairment. In addition, previous studies found inconsistent results regarding the association between migrai...

    Authors: Lihua Gu, Yanjuan Wang and Hao Shu
    Citation: The Journal of Headache and Pain 2022 23:88
    Content type: Research Published on:

  10. The onset and duration of spontaneous migraine attacks are most often difficult to predict which, in turn, makes it challenging to study the neurobiologic underpinnings of the disease in a controlled experimen...

    Authors: Håkan Ashina, Rune Häckert Christensen and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:87
    Content type: Review Published on:

  11. Calcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary headache centre.

    Authors: Michael Lowe, Lesley Murray, Alok Tyagi, George Gorrie, Sarah Miller and Krishna Dani
    Citation: The Journal of Headache and Pain 2022 23:86
    Content type: Research Published on:

  12. Headache attributed to intracranial endovascular procedures is described in the ICHD-3. Our aim was to study the frequency and characteristics of headache specifically related to thrombectomy in patients with ...

    Authors: Daniel Gallo, Leire Manrique, Marcos Polanco, Andrés González-Mandly, Eduardo Torres, Enrique Palacio, José Luis Vázquez, Sara Pérez-Pereda, Vicente González-Quintanilla, Jorge Madera and Julio Pascual
    Citation: The Journal of Headache and Pain 2022 23:85
    Content type: Research Published on:

  13. Large numbers of people with headache who would benefit are not reached by headache services. Among the causes are poor or disorganized provision of headache services, but reluctance to seek healthcare has fre...

    Authors: Thien Phu Do, Simon Stefansen, Mikala Dømgaard, Timothy J. Steiner and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:84
    Content type: Research Published on:

  14. The pathogenesis of migraine chronification remains unclear. Functional and structural magnetic resonance imaging studies have shown impaired functional and structural alterations in the brains of patients wit...

    Authors: Wei Wang, Xueyan Zhang, Xiaoyan Bai, Yingkui Zhang, Ziyu Yuan, Hefei Tang, Zhiye Li, Zhangxuan Hu, Yaqing Zhang, Xueying Yu, Binbin Sui and Yonggang Wang
    Citation: The Journal of Headache and Pain 2022 23:83
    Content type: Research Published on:

  15. Authors: Ruth Ruscheweyh, Theresa Klonowski, Gudrun Goßrau, Torsten Kraya, Charly Gaul, Andreas Straube, Tim Patrick Jürgens, Jörg Scheidt and Stefanie Förderreuther
    Citation: The Journal of Headache and Pain 2022 23:82
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2022 23:74

  16. Sensitization to sensory stimuli is an essential feature of migraine attacks. The relationship between the clinical course of migraine and increased sensitivity to olfactory stimuli has been little studied so ...

    Authors: Gudrun Gossrau, Marie Frost, Anna Klimova, Thea Koch, Rainer Sabatowski, Coralie Mignot and Antje Haehner
    Citation: The Journal of Headache and Pain 2022 23:81
    Content type: Research Published on:

  17. Several functional neuroimaging studies on healthy controls and patients with migraine with aura have shown that the activation of functional networks during visual stimulation is not restricted to the striate...

    Authors: Gianluca Coppola, Ilenia Corbelli, Antonio Di Renzo, Andrea Chiappiniello, Pietro Chiarini, Vincenzo Parisi, Giorgio Guercini, Paolo Calabresi, Roberto Tarducci and Paola Sarchielli
    Citation: The Journal of Headache and Pain 2022 23:80
    Content type: Research Published on:

  18. Targeting fatty acid amide hydrolase (FAAH) is a promising therapeutic strategy to combat certain forms of pain, including migraine headache. FAAH inhibitors, such as the O-biphenyl-3-yl carbamate URB597, have be...

    Authors: Rosaria Greco, Chiara Demartini, Anna Maria Zanaboni, Miriam Francavilla, Angelo Reggiani, Natalia Realini, Rita Scarpelli, Daniele Piomelli and Cristina Tassorelli
    Citation: The Journal of Headache and Pain 2022 23:79
    Content type: Research Published on:

  19. Migraine represents a serious burden for national health systems. However, preventive treatment is not optimally applied to reduce the severity and frequency of headache attacks and the related expenses. Our a...

    Authors: Pablo Irimia, David García-Azorín, Mercedes Núñez, Sílvia Díaz-Cerezo, Pepa García de Polavieja, Tommaso Panni, Aram Sicras-Navarro, Antoni Sicras-Mainar and Antonio Ciudad
    Citation: The Journal of Headache and Pain 2022 23:78
    Content type: Research Published on:

  20. Tension-type headache (TTH) is the most prevalent neurological disorder. As there is a gap in the literature regarding the disease burden attributable to TTH in the Middle East and North Africa (MENA) region, ...

    Authors: Saeid Safiri, Ali-Asghar Kolahi, Maryam Noori, Seyed Aria Nejadghaderi, Armin Aslani, Mark J. M. Sullman, Mehdi Farhoudi, Mostafa Araj-Khodaei, Gary S. Collins, Jay S. Kaufman and Kurosh Gharagozli
    Citation: The Journal of Headache and Pain 2022 23:77
    Content type: Research Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:94

  21. In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking. This study aimed to explore the relative efficacy of lasmid...

    Authors: Pepa Polavieja, Mark Belger, Shiva Kumar Venkata, Stefan Wilhelm and Erin Johansson
    Citation: The Journal of Headache and Pain 2022 23:76
    Content type: Research Published on:

  22. Migraine is the second most common form of headache disorder and the second leading cause of disability worldwide. Cognitive symptoms ranked second resulting in migraine-related disability, after pain. P2X7 re...

    Authors: Yajuan Wang, Zhengming Shan, Lily Zhang, Shanghua Fan, Yanjie Zhou, Luyu Hu, Yue Wang, Weidong Li and Zheman Xiao
    Citation: The Journal of Headache and Pain 2022 23:75
    Content type: Research Published on:

  23. Although good treatment options exist for many headache disorders, not all patients benefit and disability continues to be large. To design strategies for improving headache care, real-world data observing sta...

    Authors: Ruth Ruscheweyh, Theresa Klonowski, Gudrun Goßrau, Torsten Kraya, Charly Gaul, Andreas Straube, Tim Patrick Jürgens, Jörg Scheidt and Stefanie Förderreuther
    Citation: The Journal of Headache and Pain 2022 23:74
    Content type: Research Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:82

  24. Growing evidence supports the important role of persistent sodium currents (INaP) in the neuronal excitability of various central neurons. However, the role of tetrodotoxin-resistant (TTX-R) Na+ channel-mediated ...

    Authors: Michiko Nakamura and Il-Sung Jang
    Citation: The Journal of Headache and Pain 2022 23:73
    Content type: Research Published on:

  25. Nucleus accumbens (NAcc) played an important role in pain mediation, and presents changes of neuronal plasticity and functional connectivity. However, less is known about altered perfusion of NAcc in chronic m...

    Authors: Mengqi Liu, Yijie Sun, Xin Li and Zhiye Chen
    Citation: The Journal of Headache and Pain 2022 23:72
    Content type: Research Published on:

  26. Gut microbial dysbiosis and gut-brain axis dysfunction have been implicated in the pathophysiology of migraine. However, it is unclear whether migraine-related cephalic allodynia could induce the alteration of...

    Authors: Shuai Miao, Wenjing Tang, Heng Li, Bozhi Li, Chunxiao Yang, Wei Xie, Tao Wang, Wenhao Bai, Zihua Gong, Zhao Dong and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2022 23:71
    Content type: Research Published on:

  27. Migraine is a chronic disease characterized by episodic headache attacks. No recent studies have, however been conducted on the epidemiology of migraine or the treatment landscape in Japan. This study was cond...

    Authors: Fumihiko Sakai, Koichi Hirata, Hisaka Igarashi, Takao Takeshima, Takeo Nakayama, Hiromi Sano, Hiroyuki Kondo, Yoshiyuki Shibasaki and Nobuyuki Koga
    Citation: The Journal of Headache and Pain 2022 23:70
    Content type: Research Published on:

    The Author Correction to this article has been published in The Journal of Headache and Pain 2022 23:164

  28. Clinical trials have demonstrated galcanezumab as safe and effective in migraine prevention. However, real-life data are still lacking and overlook the impact of galcanezumab on those different migraine facets...

    Authors: Marcello Silvestro, Alessandro Tessitore, Ilaria Orologio, Rosa De Micco, Lorenzo Tartaglione, Francesca Trojsi, Gioacchino Tedeschi and Antonio Russo
    Citation: The Journal of Headache and Pain 2022 23:69
    Content type: Research Published on:

  30. A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized contr...

    Authors: Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, Lars Bendtsen, Christina I. Deligianni, Raquel Gil-Gouveia, Zaza Katsarava, Antoinette MaassenVanDenBrink, Paolo Martelletti, Dimos-Dimitrios Mitsikostas, Raffaele Ornello, Uwe Reuter, Margarita Sanchez-del-Rio, Alexandra J. Sinclair, Gisela Terwindt, Derya Uluduz…
    Citation: The Journal of Headache and Pain 2022 23:67
    Content type: Consensus Article Published on:

  31. In this editorial we aim to provide an overview of Narrative-based Medicine (NBM) and highlight what it may offer to the care of individuals with headache disorders.

    Authors: Christian Lampl, Simona Sacco and Paolo Martelletti
    Citation: The Journal of Headache and Pain 2022 23:66
    Content type: Brief Report Published on:

  32. The debilitating nature of migraine attacks is widely established; however, less is known about how the interictal burden (i.e., how patients are affected in-between migraine episodes) of migraine impacts on p...

    Authors: Siu Hing Lo, Katy Gallop, Timothy Smith, Lauren Powell, Karissa Johnston, Lena T. Hubig, Emma Williams, Vladimir Coric, Linda Harris, Gilbert L’Italien and Andrew J. Lloyd
    Citation: The Journal of Headache and Pain 2022 23:65
    Content type: Research Published on:

  33. Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi and Fabrizio Vernieri
    Citation: The Journal of Headache and Pain 2022 23:64
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2022 23:46

  34. Initial evidence have shown the short-term efficacy of sTMS in the acute and preventive treatment of migraine. It is unknown whether this treatment approach in the long-term is effective and well tolerated in ...

    Authors: J.O. Lloyd, B. Hill, M. Murphy, A. Al-Kaisy, A. P. Andreou and G. Lambru
    Citation: The Journal of Headache and Pain 2022 23:63
    Content type: Research article Published on:

  35. Despite the prevalence of concussions in young athletes, the impact of headaches on neurocognitive function at baseline is poorly understood. We analyze the effects of a history of headache treatment on baseli...

    Authors: Lily McCarthy, Theodore C. Hannah, Adam Y. Li, Alexander J. Schupper, Eugene Hrabarchuk, Roshini Kalagara, Muhammad Ali, Alex Gometz, Mark R. Lovell and Tanvir F. Choudhri
    Citation: The Journal of Headache and Pain 2022 23:62
    Content type: Research article Published on:

  36. Clinical trials have shown that erenumab is effective and well-tolerated for the preventive treatment of chronic migraine. To extend the results from clinical trials, we assessed the real-world efficacy and sa...

    Authors: Christopher Kjaer Cullum, Thien Phu Do, Messoud Ashina, Lars Bendtsen, Sarah Sonja Hugger, Afrim Iljazi, Julia Gusatovic, Josefin Snellman, Cristina Lopez-Lopez, Håkan Ashina and Faisal Mohammad Amin
    Citation: The Journal of Headache and Pain 2022 23:61
    Content type: Research Published on:

  37. Several preclinical and clinical lines of evidence suggest a role of neuroinflammation in migraine. Neuroimaging offers the possibility to investigate and localize neuroinflammation in vivo in patients with migra...

    Authors: Rune Häckert Christensen, Cédric Gollion, Faisal Mohammad Amin, Michael A. Moskowitz, Nouchine Hadjikhani and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:60
    Content type: Review Published on:

  38. The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients. CGRP activates...

    Authors: Sanne Hage La Cour, Kiki Juhler, Lisette J. A. Kogelman, Jes Olesen, Dan Arne Klærke, David Møbjerg Kristensen and Inger Jansen-Olesen
    Citation: The Journal of Headache and Pain 2022 23:59
    Content type: Research Published on:

  39. Cluster headache is a less-prevalent primary headache disorder but is overrepresented with regards to use of health care and social services. More insight into the socioeconomic impact is required.

    Authors: Anja Sofie Petersen, Nunu Lund, Agneta Snoer, Rigmor Højland Jensen and Mads Barloese
    Citation: The Journal of Headache and Pain 2022 23:58
    Content type: Research Published on:

  40. Authors: Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow and Christian Lampl
    Citation: The Journal of Headache and Pain 2022 23:57
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2021 22:141

  41. Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy a...

    Authors: Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, Oscar Patterson-Lomba, Michael J. Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu and Rajeev Ayyagari
    Citation: The Journal of Headache and Pain 2022 23:56
    Content type: Research article Published on:

  42. Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerabil...

    Authors: Hannah Schenk, Dagny Holle, Michael Nsaka, Christoph Kleinschnitz, Martin Glas and Armin Scheffler
    Citation: The Journal of Headache and Pain 2022 23:55
    Content type: Research Published on:

  43. Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patient...

    Authors: Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen and Maurice T. Driessen
    Citation: The Journal of Headache and Pain 2022 23:54
    Content type: Research article Published on:

  44. Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key ro...

    Authors: Alexandre O. Gérard, Diane Merino, Elise K. Van Obberghen, Fanny Rocher, Alexandre Destere, Michel Lantéri-Minet and Milou-Daniel Drici
    Citation: The Journal of Headache and Pain 2022 23:53
    Content type: Research Published on:

  45. The discovery of the prominent action of Calcitonin Gene Related Peptide –CGRP- on trigeminal afferents and meningeal vessels, opened a new era in migraine treatment. However, how the block of nociceptive affe...

    Authors: Marina de Tommaso, Marianna La Rocca, Silvia Giovanna Quitadamo, Katia Ricci, Giusy Tancredi, Livio Clemente, Eleonora Gentile, Elena Ammendola and Marianna Delussi
    Citation: The Journal of Headache and Pain 2022 23:52
    Content type: Research Published on:

  46. Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi and Fabrizio Vernieri
    Citation: The Journal of Headache and Pain 2022 23:51
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2022 23:46

  47. Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inade...

    Authors: Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, Sihui Zhao, Anand R. Shewale, Jordan E. Lateiner and David W. Dodick
    Citation: The Journal of Headache and Pain 2022 23:50
    Content type: Research article Published on:

  48. The Global Campaign against Headache, as a collaborative activity with the World Health Organization (WHO), was formally launched in Copenhagen in March 2004. In the month it turns 18, we review its activities...

    Authors: Timothy J. Steiner, Gretchen L. Birbeck, Rigmor H. Jensen, Paolo Martelletti, Lars Jacob Stovner, Derya Uluduz, Matilde Leonardi, Jes Olesen and Zaza Katsarava
    Citation: The Journal of Headache and Pain 2022 23:49
    Content type: Review Published on:

  49. Eptinezumab 100 mg and 300 mg met the primary efficacy endpoint in both PROMISE clinical trials, significantly reducing frequency of monthly migraine days over Weeks 1‒12. The objective of this analysis was to...

    Authors: Rami Apelian, Lee Boyle, Joe Hirman and Divya Asher
    Citation: The Journal of Headache and Pain 2022 23:48
    Content type: Research article Published on:

  50. According to the Global Burden of Disease (GBD) study, headache disorders are among the most prevalent and disabling conditions worldwide. GBD builds on epidemiological studies (published and unpublished) whic...

    Authors: Lars Jacob Stovner, Knut Hagen, Mattias Linde and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2022 23:34
    Content type: Review article Published on:
Submit manuscript

Official journal of

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.1 - 5-year Impact Factor
    2.002 - SNIP (Source Normalized Impact per Paper)
    1.593 - SJR (SCImago Journal Rank)

    2022 Speed
    2 days submission to first editorial decision for all manuscripts (Median)
    49 days submission to accept (Median)

    2022 Usage
    4,377,089 downloads
    9,457 Altmetric mentions

  • ISSN: 1129-2377 (electronic)
  • ISSN: 1129-2369 (print)

Related reading

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us